Merck (MRK) stock achieved a 5-day winning streak, with total gains during this time reaching 6.9%. The company’s market ...

Merck (MRK) closed at $106.45 in the latest trading session, marking a +1.34% move from the prior day. This change outpaced the S&P 500's 0.32% gain on the day. Elsewhere, the Dow saw an upswing of 0.

We recently published 8 Stocks on Jim Cramer’s Radar. Merck & Co., Inc. (NYSE:MRK) is one of the stocks on Jim Cramer’s ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look more into that and determine whether now is a good time to buy shares.

It doesn't have the highest yield, but it has enviable dividend coverage and a long history of surviving in a competitive ...

Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...

Looking at options history for Merck & Co (NYSE: MRK) we detected 13 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

Merck's shares have lagged the market over the past year, but the company's prospects are still strong, at least for those willing to hold onto the stock for a while. Should you invest $1,000 in Merck ...

Merck stock reached a new 52-week high, hitting $106.08, reflecting a steady upward trend in the pharmaceutical giant’s market performance. According to InvestingPro data, the stock is trading at an ...

On December 12, Morgan Stanley lifted its price target on Merck & Co., Inc. (NYSE:MRK) to $102 from $100. The firm kept an ...

We recently published Wall Street Analysts Like These 10 Stocks. Merck & Co., Inc. (NYSE:MRK) is one of the stocks analysts were recently talking about. Bill Nygren, Oakmark Funds partner and CIO, ...

Pfizer's Eliquis, a blood thinner and one of its best-selling therapies, will lose patent exclusivity within the next few ...